Quick Takeaways
- Adaptimmune Therapeutics PLC financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q2 2025.
- Headline metric: Return On Equity -1341%.
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q2 2025.
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2025-08-11) highlights Return On Equity -1341.1%, Return On Assets -75.1%, and Operating Margin -252.3%.
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
23.6/100
Weak Confidence high
-1341%
Metric score 0.0/100
-75%
Metric score 0.0/100
Current Ratio and Quick Ratio
Return On Equity, Return On Assets, and Operating Margin
Return On Equity
-1341%
YoY: +1962%
Industry median: -47% (n=218)
Return On Assets
-75%
YoY: +244%
Industry median: -44% (n=217)
Operating Margin
-252%
YoY: +363%
Industry median: -263% (n=94)
Current Ratio
1.52x
YoY: -51%
Industry median: 3.67x (n=218)
Quick Ratio
0.69x
YoY: -74%
Industry median: 2.03x (n=83)
Debt-to-equity
-52.49x
YoY: -1531%
Industry median: 0.31x (n=169)
Revenues YoY
-54%
YoY:
Industry median: 11% (n=96)
NetIncomeLoss YoY
-134%
YoY:
Industry median: -12% (n=211)
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -1341% | +1962% |
| Return On Assets | -75% | +244% |
| Operating Margin | -252% | +363% |
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 1.52x | -51% |
| Quick Ratio | 0.69x | -74% |
| Debt-to-equity | -52.49x | -1531% |
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | -54% | |
| NetIncomeLoss YoY | -134% |
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 1,590,309,546 | +3.6% |
| Common Stock, Shares, Outstanding | 1,590,309,546 | +3.7% |
| Common Stock, Value, Issued | $2,156,000 | +3.5% |
| Weighted Average Number of Shares Outstanding, Basic | 1,584,522,868 | +3.3% |
| Weighted Average Number of Shares Outstanding, Diluted | 1,584,522,868 | +1.6% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.